|[May 15, 2014]
Batu Biologics Authors Peer-Reviewed Publication on Intravenous Vitamin C as Adjuvant to Cancer Immunotherapy
SAN DIEGO --(Business Wire)--
Batu Biologics is pleased to announce publication in the peer-reviewed
Journal of Translational Medicine detailing the rationale for its
proprietary combination approach towards augmenting the immune system in
The publication, which is freely available at http://www.translational-medicine.com/content/pdf/1479-5876-12-127.pdf,
describes molecular and cellular alterations that account for
immunotherapy associated toxicity, and how various antioxidants may be
useful in decreasing such toxicities.
Collaborators on the publication included Dr. Francesco Marincola, Chief
Research Officer of Sidra Medical and Research Center, and President of
the Society for Immunotherapy of Cancer; Dr. James Koropatnick, Director
of the London Regional Cancer Center in Ontario, Canada; and Dr. Neil
Riordan, a pioneer in scientific evaluation of oncological utility of
Last week, Batu Biologics filed patent #61/990231, which covers the use
of several formulations of antioxidants for reducing toxicities and
increasing efficacy of immunotherapy. The publication reported today is
focused on intravenous vitamin C as one such antioxidant.
"The field of ascorbic acid for the treatment of cancer was originally
highly controversial, given discrepancies in efficacy between the
original clinical trials of Linus Pauling, and the Mayo Cliic trials.
However, work by Dr. Neil Riordan, who is the senior author of this
paper, demonstrated that only by intravenous administration it is
possible to achieve high enough concentrations of ascorbic acid achieved
in order to induce tumor death1, studies which were
subsequently validated by the NIH2," stated Andy Kim, VP of
Scientific Research for Batu Biologics. "In the current publication, the
utility of intravenous ascorbic acid as a means of reducing toxicity of
immunotherapy is presented. To our knowledge, this is the first time
that members of the conventional cancer establishment have given support
to integration of a holistic approach, such as intravenous ascorbic
acid, in combination with cancer immune therapy."
"Although Batu Biologics is highly focused on the clinical development
of ValloVax, a cancer vaccine targeting tumor endothelium, from a
corporate perspective we want to ensure that we have the highest
possible chance of inducing the most benefit in patients we are
treating," commented Samuel Wagner, CEO of Batu Biologics. "Accordingly,
we are developing a variety of approaches, based on FDA approved agents,
for augmenting efficacy of our cancer vaccine. The important point is
that these 'immunological adjuvants' will be useful not only for
augmentation of ValloVax efficacy, but also for other immunotherapies in
general, thus providing possibility of licensing revenues."
It is well known that tumors possess various "immunological shields"
that protect them from attack by the body's immune system. Realization
of this led to development of the immunological checkpoint inhibitors,
such as Ipilimumab (Yervoy, made by Bristol Myers Squibb) which had
sales of $706 million in 20123. Batu Biologics has data
supporting the concept of repositioning existing drugs, such as
intravenous ascorbic acid, to accomplish a similar attenuation of immune
suppression, thus allowing for increased efficacy of immunotherapy, with
About Batu Biologics: Batu Biologics is a preclinical
biopharmaceutical company focusing on developing and commercializing
allogeneic cell therapies in the area of immune modulation. Our products
are centered around the idea of creating or breaking immune tolerance.
The company is currently in the preclinical stages of drug development
for its two flagship products: Immstem and Vallovax. Batu Biologics has
filed two provisional patents in the field of cancer immunotherapy and
plans to significantly expand its IP in 2014.
9255 Towne Centre Drive
Diego, CA (News - Alert) 92121
Janssen Research and Development
San Diego, CA 92121
1 Casciari et al. Br J Cancer. 2001 Jun 1;84(11):1544-50.
2 Chen et al. Proc Natl Acad Sci U S A. 2008 Aug
[ Back To Cloud Contact Center's Homepage ]